Elicio Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 28.21 million compared to USD 26.4 million a year ago. Basic loss per share from continuing operations was USD 1.62 compared to USD 1.73 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.98 USD | +5.70% | +4.72% | -4.32% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.32% | 7.72Cr | |
+55.70% | 5.57TCr | |
+41.08% | 3.99TCr | |
-5.39% | 3.96TCr | |
-5.56% | 2.82TCr | |
+16.46% | 2.63TCr | |
-20.56% | 1.89TCr | |
+33.03% | 1.22TCr | |
+25.85% | 1.21TCr | |
+2.72% | 1.21TCr |
- Stock Market
- Equities
- ELTX Stock
- News Elicio Therapeutics, Inc.
- Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022